Metformin recall reasons
Pro Research Analysisby 
Searched over 200M research papers
Metformin Recall Reasons: NDMA Contamination in Drug Products
NDMA Carcinogenic Impurity in Metformin Extended-Release (ER) Formulations
The primary reason for metformin recalls has been the detection of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in certain batches of metformin, especially in the extended-release (ER) formulations. Regulatory agencies, including the FDA, found elevated levels of NDMA in ER metformin products, while immediate-release (IR) formulations were generally not affected to the same extent 1267.
Regulatory Testing and International Collaboration on Nitrosamine Detection
Extensive international testing and regulatory collaboration revealed that only a subset of metformin batches contained NDMA above the acceptable daily intake limit (96 ng/day). In a large-scale analysis, about 17.8% of finished dosage form samples tested had NDMA levels exceeding safety standards, prompting recalls of those specific batches. However, the majority of metformin products tested met quality and safety requirements .
Root Causes of NDMA Formation in Metformin
Investigations into the source of NDMA contamination identified that the interaction between dimethylamine (DMA), present in the active pharmaceutical ingredient (API), and atmospheric nitrogen dioxide (NO2) during manufacturing could lead to the formation of NDMA. This reaction was particularly noted during processes such as fluidized bed granulation, which is commonly used in tablet production .
Broader Context: Nitrosamine Impurities in Pharmaceuticals
The issue of nitrosamine impurities is not unique to metformin. Other drugs, such as valsartan, ranitidine, and nizatidine, have also been recalled for similar reasons. The presence of genotoxic and carcinogenic nitrosamines in pharmaceuticals has become a significant regulatory concern, leading to updated guidelines and stricter controls in drug manufacturing .
Impact of Recalls and Ongoing Safety Measures
Following the recalls, regulatory agencies have worked closely with manufacturers to identify the root causes of NDMA contamination and implement corrective actions to prevent future occurrences. The recalls were effective in reducing NDMA levels in ER metformin products below the FDA threshold, although some IR samples still showed contamination even after the recalls 26. The recalls did not significantly impact the price or availability of metformin, and safer alternatives remained accessible to patients .
Conclusion
Metformin recalls were primarily driven by the detection of NDMA, a carcinogenic impurity, in certain ER formulations. The contamination was traced to specific manufacturing processes involving DMA and atmospheric NO2. Regulatory agencies continue to monitor, test, and collaborate internationally to ensure the safety of metformin and other pharmaceuticals, with ongoing efforts to eliminate nitrosamine impurities from the drug supply 1235+2 MORE.
Sources and full results
Most relevant research papers on this topic